Qingfeng Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7641433/publications.pdf

Version: 2024-02-01

102	4,935	87886	91872
papers	citations	38 h-index	69 g-index

103	103	103	6822
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity. Journal of Immunology, 2009, 183, 6251-6261.	0.8	485
2	FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research, 2010, 51, 771-784.	4.2	363
3	The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis. PLoS ONE, 2011, 6, e25637.	2.5	297
4	Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends in Pharmacological Sciences, 2009, 30, 570-580.	8.7	295
5	Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21783-21788.	7.1	251
6	Antiatherosclerotic effect of farnesoid X receptor. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 296, H272-H281.	3.2	166
7	The bile acid sensor FXR regulates insulin transcription and secretion. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 363-372.	3.8	153
8	The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo. Molecular Pharmacology, 2006, 70, 1164-1173.	2.3	145
9	The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis. Journal of Immunology, 2009, 183, 6657-6666.	0.8	134
10	5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 447-458.	2.5	130
11	Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Progress in Lipid Research, 2010, 49, 171-185.	11.6	121
12	Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice. Circulation, 2013, 127, 2114-2124.	1.6	114
13	Inhibition of NF-Î°B by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. European Journal of Pharmacology, 2011, 668, 317-324.	3.5	97
14	VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. PLoS ONE, 2012, 7, e45425.	2.5	90
15	Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome. PLoS ONE, 2013, 8, e63893.	2.5	89
16	Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochemical Pharmacology, 2010, 80, 1700-1707.	4.4	86
17	Humanized Mice as Unique Tools for Human-Specific Studies. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 245-266.	2.3	84
18	Probiotics Modulate Intestinal Expression of Nuclear Receptor and Provide Counter-Regulatory Signals to Inflammation-Driven Adipose Tissue Activation. PLoS ONE, 2011, 6, e22978.	2.5	83

#	Article	IF	Citations
19	The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation. PLoS ONE, 2013, 8, e54472.	2.5	82
20	The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochemical Pharmacology, 2009, 78, 1214-1223.	4.4	74
21	FXR an emerging therapeutic target for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine, 2010, 14, 79-92.	3.6	66
22	The methionine connection: Homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. Hepatology, 2008, 47, 659-667.	7.3	63
23	Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis. PLoS ONE, 2012, 7, e30443.	2.5	62
24	Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment. Current Medicinal Chemistry, 2010, 17, 139-159.	2.4	59
25	Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2011, 1809, 157-165.	1.9	59
26	Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World Journal of Gastroenterology, 2009, 15, 2097.	3.3	54
27	Total Synthesis and Pharmacological Characterization of Solomonsterol A, a Potent Marine Pregnane-X-Receptor Agonist Endowed with Anti-Inflammatory Activity. Journal of Medicinal Chemistry, 2011, 54, 4590-4599.	6.4	53
28	Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs. Biomaterials, 2015, 63, 146-157.	11.4	52
29	Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. European Journal of Pharmacology, 2011, 665, 29-39.	3.5	51
30	Dissociation of Intestinal and Hepatic Activities of FXR and LXRÎ± Supports Metabolic Effects of Terminal Ileum Interposition in Rodents. Diabetes, 2013, 62, 3384-3393.	0.6	51
31	Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB Journal, 2012, 26, 3021-3031.	0.5	48
32	Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Scientific Reports, 2016, 6, 30802.	3.3	48
33	Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NOâ€pegylated epirubicin. FASEB Journal, 2006, 20, 765-767.	0.5	47
34	Plakilactones from the Marine Sponge Plakinastrella mamillaris. Discovery of a New Class of Marine Ligands of Peroxisome Proliferator-Activated Receptor Î³. Journal of Medicinal Chemistry, 2012, 55, 8303-8317.	6.4	47
35	CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. Translational Oncology, 2013, 6, 784-793.	3.7	47
36	Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-Î³-STAT-1 pathway in macrophages. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 564-573.	3.8	43

#	Article	IF	Citations
37	SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-Î³ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. Inflammation Research, 2011, 60, 577-587.	4.0	42
38	Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Medicinal Chemistry, 2012, 4, 877-891.	2.3	42
39	Hydrogen Sulphide Induces Î¼ Opioid Receptor-Dependent Analgesia in a Rodent Model of Visceral Pain. Molecular Pain, 2010, 6, 1744-8069-6-36.	2.1	40
40	4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. Steroids, 2012, 77, 484-495.	1.8	40
41	A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice. Scientific Reports, 2017, 7, 16642.	3.3	33
42	Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. British Journal of Pharmacology, 2011, 164, 1929-1938.	5.4	32
43	Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms. Translational Oncology, 2019, 12, 987-995.	3.7	32
44	A humanized mouse model to study mast cells mediated cutaneous adverse drug reactions. Journal of Leukocyte Biology, 2020, 107, 797-807.	3.3	29
45	Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anti-Cancer Drugs, 2007, 18, 1081-1091.	1.4	28
46	The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice. PLoS ONE, 2010, 5, e13238.	2.5	28
47	Calcineurin-mediated IL-2 production by CD11chighMHCII+ myeloid cells is crucial for intestinal immune homeostasis. Nature Communications, 2018, 9, 1102.	12.8	26
48	Solomonsterol A, a Marine Pregnane-X-Receptor Agonist, Attenuates Inflammation and Immune Dysfunction in a Mouse Model of Arthritis. Marine Drugs, 2014, 12, 36-53.	4.6	25
49	Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinomaâ€“Immune Humanized Mouse Model. Hepatology, 2021, 74, 1395-1410.	7.3	25
50	The HIV Matrix Protein p17 Subverts Nuclear Receptors Expression and Induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes. PLoS ONE, 2012, 7, e35924.	2.5	25
51	Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. European Journal of Pharmacology, 2012, 674, 143-152.	3.5	21
52	The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1522-1531.	3.8	20
53	Humanized Mouse Models for the Study of Infection and Pathogenesis of Human Viruses. Viruses, 2018, 10, 643.	3.3	19
54	Potential Applications and Perspectives of Humanized Mouse Models. Annual Review of Animal Biosciences, 2022, 10, 395-417.	7.4	18

#	Article	IF	Citations
55	Activation of the bile acid receptor <scp>GPBAR</scp>1 protects against gastrointestinal injury caused by nonâ€steroidal antiâ€inflammatory drugs and aspirin in mice. British Journal of Pharmacology, 2013, 168, 225-237.	5.4	17
56	An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 162.	17.0	17
57	Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-Î³-dependent manner. Antiviral Therapy, 2012, 17, 669-678.	1.0	16
58	Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS ONE, 2017, 12, e0184127.	2.5	16
59	The Inflammasome Adaptor ASC Intrinsically Limits CD4+ T-Cell Proliferation to Help Maintain Intestinal Homeostasis. Frontiers in Immunology, 2019, 10, 1566.	4.8	15
60	A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. Pharmacological Research, 2009, 59, 319-329.	7.1	14
61	FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. Pharmacological Research, 2013, 77, 1-10.	7.1	14
62	Epigenetic Modulation by Methionine Deficiency Attenuates the Potential for Gastric Cancer Cell Dissemination. Journal of Gastrointestinal Surgery, 2013, 17, 39-49.	1.7	14
63	Antiâ€inflammatory Activity of a New Class of Nitric Oxide Synthase Inhibitors That Release Nitric Oxide. ChemMedChem, 2008, 3, 1580-1588.	3.2	12
64	Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2018, 24, 123-135.	1.9	12
65	Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells, 2019, 8, 604.	4.1	12
66	Bat-mouse bone marrow chimera: a novel animal model for dissecting the uniqueness of the bat immune system. Scientific Reports, 2018, 8, 4726.	3.3	11
67	Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C. Molecular BioSystems, 2012, 8, 1412.	2.9	10
68	Calcineurin B in CD4+ T Cells Prevents Autoimmune Colitis by Negatively Regulating the JAK/STAT Pathway. Frontiers in Immunology, 2018, 9, 261.	4.8	10
69	Enterovirus A71 Infection Activates Human Immune Responses and Induces Pathological Changes in Humanized Mice. Journal of Virology, 2019, 93, .	3.4	9
70	A role for proteinase-activated receptor-1 in inflammatory bowel diseases. Journal of Clinical Investigation, 2006, 116, 2056-2056.	8.2	5
71	Hydrogen Sulfide in Gastrointestinal and Liver Physiopathology. Inflammation and Allergy: Drug Targets, 2011, 10, 92-102.	1.8	4
72	Inhibition of NF-kB by a PXR-Dependent Pathway Mediates Counter-regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells. Gastroenterology, 2011, 140, S-639.	1.3	3

#	Article	IF	Citations
73	M1735 FXR Activation Reverses Insulin Resistance and Protects Against NASH Development,. Gastroenterology, 2009, 136, A-420-A-421.	1.3	2
74	Molecular Determinants of Gastrointestinal and Liver Cancers: Role of Bile Acid Activated Nuclear Receptors. Current Topics in Medicinal Chemistry, 2012, 12, 625-636.	2.1	2
75	In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. European Journal of Pharmacology, 2014, 723, 194-201.	3.5	2
76	the Bile Acid Sensor FXR Induces the Glucocorticoid Receptor in the Liver in a Promoter-Dependent Manner. Gastroenterology, 2011, 140, S-977.	1.3	1
77	16 A Dark Side of FXR Activation in Cholestasis. FXR Is a Negative Regulator of MRP4. Gastroenterology, 2009, 136, A-1.	1.3	0
78	604 H2S Induces Analgesia Is Mediated In Vivo Activation of Î¼ Opioid Receptor and PI3K/AKT Pathway Activation. Gastroenterology, 2009, 136, A-98.	1.3	0
79	S2070 FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis. Gastroenterology, 2009, 136, A-324.	1.3	0
80	M1739 Ml3403, a New p38 MAPK Inhibitor, Corrects Immune Dysfunction in Rodent Models of Chronic Inflammatory Disorders. Gastroenterology, 2010, 138, S-409.	1.3	0
81	T1965 Bile Acids Induce Rat PPARÎ²2 Gene via Activation of Farnesoid X Receptor.. Gastroenterology, 2010, 138, S-838.	1.3	0
82	542 Farnesoid X Receptor Regulates Glutamate Metabolism: Relevance for Hepatic Encephalopathy. Gastroenterology, 2010, 138, S-791.	1.3	0
83	773 The Bile Acid Sensor FXR Modulates Hydrogen Sulfide Generation in the Gastric Mucosa and Protects Against Injury Caused by Aspirin. Gastroenterology, 2010, 138, S-108.	1.3	0
84	1079 Macrolide Derivatives Devoid of Antibiotic Activity Correct Immune Dysfunction in Rodent Models of Inflammatory Bowel Diseases.. Gastroenterology, 2010, 138, S-157.	1.3	0
85	M1802 Rifaximin is a Human Pregnane X Receptor Activator in Human Colon Epithelial Cells and Regulate Detoxification Pathway. Gastroenterology, 2010, 138, S-422.	1.3	0
86	Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis. Gastroenterology, 2011, 140, S-904.	1.3	0
87	Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs. Gastroenterology, 2011, 140, S-652.	1.3	0
88	Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis.. Gastroenterology, 2011, 140, S-499.	1.3	0
89	Molecular Determinants of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Model of Peritoneal Gastric Cancer Carcinogenesis. Gastroenterology, 2011, 140, S-1027.	1.3	0
90	The Bile Acids Receptor TGR5 is an Essential Modulator of Intestinal Membrane Permeability and Exerts Anti-Inflammatory Activities in Rodent Model of Colitis. Gastroenterology, 2011, 140, S-26.	1.3	0

#	Article	IF	Citations
91	Mechanistic Role of p38 MAPK in Gastric Cancer Dissemination in a Rodent Model Peritoneal Metastasis. Gastroenterology, 2011, 140, S-1061.	1.3	0
92	Tu2041 Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE-/- Mice. Gastroenterology, 2012, 142, S-909.	1.3	0
93	1009 Epigenetic Modulation of Adhesion and Proliferation Pathways by Methionine Deficiency Attenuates Potential for Dissemination of Gastric Cancer Cells. Gastroenterology, 2012, 142, S-1048.	1.3	0
94	1108 Reciprocal Regulation of TLRS and Nuclear Receptors: IRF-7 Dependent Regulation of FXR Mediates Counter-Regulatory Effects of TLR-9 in Colitis. Gastroenterology, 2012, 142, S-200.	1.3	0
95	Tu1920 a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation. Gastroenterology, 2012, 142, S-878.	1.3	0
96	Su1733 The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs. Gastroenterology, 2012, 142, S-491.	1.3	0
97	Tu1417 Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation. Gastroenterology, 2012, 142, S-827.	1.3	0
98	Su2132 Dissociation of Activity of Ileal and Liver FXR Mediates Metabolic Effects in a Rodent Model of Bariatric Surgery.. Gastroenterology, 2013, 144, S-1090.	1.3	0
99	Su1985 The CCR5 Antagonist Maraviroc Reduces the Potential for Gastric Cancer Dissemination in Rodent Models of Peritoneal Metastasis.. Gastroenterology, 2013, 144, S-524.	1.3	0
100	Tu2023 A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors.. Gastroenterology, 2013, 144, S-907.	1.3	0
101	Mo1915 Genetic Ablation and Pharmacological Blockade of CCR5 by the anti-HIV Small Molecule Inhibitor Maraviroc Inhibits Leukocyte Trafficking and Protects Against Mucosal Inflammation in Murine Models Colitis. Gastroenterology, 2016, 150, S815.	1.3	0
102	A Hydrogenâ€Sulfide Releasing Derivative of Mesalamine Exhibits Markedly Enhanced Antiâ€Inflammatory Effects in Experimental Colitis. FASEB Journal, 2007, 21, A131.	0.5	0